Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Bioadaptives (BDPT) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to $269540.0.

  • Bioadaptives' Operating Expenses rose 12104.13% to $269540.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 24096.36%. This contributed to the annual value of $606120.0 for FY2024, which is 15282.39% up from last year.
  • Per Bioadaptives' latest filing, its Operating Expenses stood at $269540.0 for Q3 2025, which was up 12104.13% from $280282.0 recorded in Q2 2025.
  • Bioadaptives' Operating Expenses' 5-year high stood at $337339.0 during Q4 2024, with a 5-year trough of $20955.0 in Q1 2023.
  • Its 5-year average for Operating Expenses is $143160.1, with a median of $121941.0 in 2024.
  • As far as peak fluctuations go, Bioadaptives' Operating Expenses soared by 82061.76% in 2021, and later tumbled by 8810.72% in 2023.
  • Quarter analysis of 5 years shows Bioadaptives' Operating Expenses stood at $178876.0 in 2021, then crashed by 84.16% to $28332.0 in 2022, then soared by 127.6% to $64483.0 in 2023, then surged by 423.14% to $337339.0 in 2024, then decreased by 20.1% to $269540.0 in 2025.
  • Its last three reported values are $269540.0 in Q3 2025, $280282.0 for Q2 2025, and $249148.0 during Q1 2025.